This Houston startup has fresh funding to build out its data intelligence platform.  Photo via aim7.com

How many times have you forced yourself to do an arduous workout when you just weren’t feeling it? Despite what some trainers will tell you, you probably didn’t feel any better after. Sports scientist Dr. Erik Korem could have told you that, but more importantly, so could his creation, AIM7.

Marketed as “the fastest, easiest way to change your habits and improve your health,” Korem just raised a $1.3 million seed round that will bring his ambitious app to consumers in its beta form early next month.

The data intelligence platform would know that on a day that you’re stressed, that Peloton tabata ride might not be in your best interest. How? “The data from your Apple Watch or your Fitbit is just data. ‘I walked 7000 steps or I slept 8 hours,’” explains Korem. “We are the recommendation engine that makes this usable for you.”

When using AIM7, there’s no sticking to a set schedule of workouts. With both short term and long term goals in mind, the technology tells you what your body needs when you need it. On a day that your health tracking device notes that you haven’t slept well and your body is stressed, Korem says, the run you had planned may be replaced by a more realistic 20 minutes of yoga.

Korem’s team member, Dr. Chris Morris coined the term “fluid periodization” and has published academic work on the concept.

“Just because you have something written on paper doesn’t mean that your body is going to adapt to that stress,” says Korem. In the sports world, that means tailoring workouts to the immediate situation — and reaping improvements in performance.

Korem should know. He’s been using this concept for years as a High Performance director for both college and professional football teams, a trainer for gold medal Olympians and even working with the United States Department of Defense. In 2016, then-GM of the Houston Texans, Rick Smith, hired Korem to work his magic on his team as one of pro football’s first directors of sports science. His time with the Texans ended in 2018, but it provided him with a key investor—Smith himself.

The $1.3 million, which Korem says AIM7 will use to hire more engineers to add to his team, owes much to his success at last month’s Houston-based Dress Up Buttercup pitch contest, Build Up Buttercup. Hosted by local fashion blogger and influencer Dede Raad and her husband, Ted, the contest gave Korem a forum to share his story.

“I didn’t quite understand the scope of it,” he admits. “I didn’t realize it was going to be this full ‘Shark Tank’ thing, but I prepared and memorized my pitch. It’s just game time, right?”

Other investors include John Jarrett of Academy Sports and Outdoors, former Cleveland Browns coach Freddie Kitchens, and Jamaican track-and-field Olympian Veronica Campbell Brown, whom Korem has trained for years.

Currently, AIM7 boasts a remote team of five full-time employees as well as many more part-time helpers. As the brand, which Korem started in 2020, takes off, Korem says, “My dream is to build a standalone health and wellness tech company in Houston… I want to set up something really special in Houston.”

Erik Korem founded AIM7, which just closed $1.3 million in seed funding. Photo via aim7.com

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Biosciences startup becomes Texas' first decacorn after latest funding

A Dallas-based biosciences startup whose backers include millionaire investors from Austin and Dallas has reached decacorn status — a valuation of at least $10 billion — after hauling in a series C funding round of $200 million, the company announced this month. Colossal Biosciences is reportedly the first Texas startup to rise to the decacorn level.

Colossal, which specializes in genetic engineering technology designed to bring back or protect various species, received the $200 million from TWG Global, an investment conglomerate led by billionaire investors Mark Walter and Thomas Tull. Walter is part owner of Major League Baseball’s Los Angeles Dodgers, and Tull is part owner of the NFL’s Pittsburgh Steelers.

Among the projects Colossal is tackling is the resurrection of three extinct animals — the dodo bird, Tasmanian tiger and woolly mammoth — through the use of DNA and genomics.

The latest round of funding values Colossal at $10.2 billion. Since launching in 2021, the startup has raised $435 million in venture capital.

In addition to Walter and Tull, Colossal’s investors include prominent video game developer Richard Garriott of Austin and private equity veteran Victor Vescov of Dallas. The two millionaires are known for their exploits as undersea explorers and tourist astronauts.

Aside from Colossal’s ties to Dallas and Austin, the startup has a Houston connection.

The company teamed up with Baylor College of Medicine researcher Paul Ling to develop a vaccine for elephant endotheliotropic herpesvirus (EEHV), the deadliest disease among young elephants. In partnership with the Houston Zoo, Ling’s lab at the Baylor College of Medicine has set up a research program that focuses on diagnosing and treating EEHV, and on coming up with a vaccine to protect elephants against the disease. Ling and the BCMe are members of the North American EEHV Advisory Group.

Colossal operates research labs Dallas, Boston and Melbourne, Australia.

“Colossal is the leading company working at the intersection of AI, computational biology, and genetic engineering for both de-extinction and species preservation,” Walter, CEO of TWG Globa, said in a news release. “Colossal has assembled a world-class team that has already driven, in a short period of time, significant technology innovations and impact in advancing conservation, which is a core value of TWG Global.”

Well-known genetics researcher George Church, co-founder of Colossal, calls the startup “a revolutionary genetics company making science fiction into science fact.”

“We are creating the technology to build de-extinction science and scale conservation biology,” he added, “particularly for endangered and at-risk species.”

Houston investment firm names tech exec as new partner

new hire

Houston tech executive Robert Kester has joined Houston-based Veriten, an energy-focused research, investment and strategy firm, as technology and innovation partner.

Kester most recently served as chief technology officer for emissions solutions at Honeywell Process Solutions, where he worked for five years. Honeywell International acquired Houston-based oil and gas technology company Rebellion Photonics, where Kester was co-founder and CEO, in 2019.

Honeywell Process Solutions shares offices in Houston with the global headquarters of Honeywell Performance Materials and Technologies. Honeywell, a Fortune 100 conglomerate, employs more than 850 people in Houston.

“We are thrilled to welcome Robert to the Veriten team,” founder and CEO Maynard Holt said in a statement, “and are confident that his technical expertise and skills will make a big contribution to Veriten’s partner and investor community. He will [oversee] every aspect of what we do, with the use case for AI in energy high on the 2025 priority list.”

Kester earned a doctoral degree in bioengineering from Rice University, a master’s degree in optical sciences from the University of Arizona and a bachelor’s degree in laser optical engineering technology from the Oregon Institute of Technology. He holds 25 patents and has more than 25 patents pending.

Veriten celebrated its third anniversary on January 10, the day that the hiring of Kester was announced. The startup launched with seven employees.

“With the addition of Dr. Kester, we are a 26-person team and are as enthusiastic as ever about improving the energy dialogue and researching the future paths for energy,” Holt added.

Kester spoke on the Houston Innovators Podcast in 2021. Listen here

.